This week in clinical cardiology.
PCI reduces mortality after STEMI in older adults.
Canagliflozin lowers kidney failure risk in T2D: CREDENCE.
Poor response to statins hikes risk of cardiovascular events.
Low LDL cholesterol may increase women’s risk of hemorrhagic stroke
This week in clinical cardiology:
Alirocumab reduces both type 1 and 2 MIs.
Despite failed primary endpoint, MI alert device has predictive value.
Look for alcohol septal ablation in the next HOCM guideline.
FDA: Forty ARBs free of nitrosamines. You can contact the Cardiocast with ideas, suggestions, stories, or questions for Dr. Dwyer by emailing us at firstname.lastname@example.org and you can follow MDedge Cardiology on Twitter at @MDedgeCardio.
This week's top stories in clinical cardiology:
Has radial access PCI been overhyped?
Hospital TAVR volume matters to patient survival.
Studies link TMAO to microbiome, reveal new heart disease target.
More chest compression–only CPR leads to increased survival rates.
You can contact the show by emailing us at email@example.com or you can follow MDedge Cardiology on Twitter at @MDedgeCardio.
This week, a novel drug that reverses ticagrelor’s effect looks promising, a new certification process for cardiologists is unveiled, intensive blood pressure monitoring may not help prevent a second stroke, and the FDA cautions against using paclitaxel coated devices.
Cardiovascular prevention guidelines downgrade aspirin, high coronary artery calcium scores carry greater risks, an Apple Watch algorithm predicts AFib, and TAVR overtakes surgery in "historic" trials.
This week in MDedge Cardiocast: A novel drug lowers LDL in on top of maximums statins, invasive cardiology is a top money maker for hospitals, a meta-analysis parses the heart and kidney benefits of new diabetes drugs, and the AHA warns that heart-harming toxins may hurt hookah smokers.
This week in MDedge Cardiocast: Infective endocarditis isn’t what it used to be, there’s a new, lower goal for Americans’ dietary intake of sodium, a drug to treat myeloma also raises heart failure risk, and Big Pharma says it can’t drop drug list prices alone.
The Food and Drug Administration could extend eligibility for Belviq to lower-risk patients, the agency says a popular gout drug raises cardiovascular risk, an AHA statement targets CV risk factors in children, and a class action suit against the American Board of Internal Medicine over MOC gets financial support from doctors.
Silent strokes are common after noncardiac surgery, troubling news about nonadherence to statins, what cardiologists need to know about ARVC, and how gender inequality in medicine affects the health of all women.
This week in MDedge Cardiocast: Most tPA-eligible stroke patients now get treated within an hour, LAA closure can be treated safely in patients with prior hemorrhagic stroke, SGLT2 inhibitors are quickly morphing from diabetes to heart failure drugs, and the MESA cardiovascular disease risk calculator can be an improvement on the ACC/AHA version.
Elevated CAC in highly active men doesn't raise risk of death, Life's Simple 7 scores can be used to modify PAD risk, medical guidance often leads atrial fibrillation patients to needlessly seek emergency care, and thinking of pregnancy as a stress test can help predict women's future cardiovascular risk.
This week in cardiology news, revised atrial fibrillation guidelines revamp anticoagulation, the SPRINT MIND results showing that tight BP control staves off mild cognitive impairment are published, the FDA discovers that nitrosamine-contaminated ARBs have been on the market for years, and subclinical hypothyroidism boosts the immediate risk of heart failure.
This week, the FDA weighs in on concerning reports about paclitaxel-coated stents, and it approves a device to treat patent ductus arteriosus in infants weighing as little as 2 pounds. Also, a treat-to-target approach for CVD risk factors decreased atherosclerosis in rheumatoid arthritis patients, and ezetimibe was effective for primary prevention in elderly patients.
This week in MDedge Cardiocast: too little sleep, too much sleep, and fragmented sleep are all linked to atherosclerosis; dabigatran matches aspirin for second stroke prevention; HDL particle subfractions may be prognostic in heart failure; and a novel drug safely reduced LDL cholesterol in statin-intolerant patients.
This week from MDedge Cardiology, a biodegradable polymer shows no long-term benefit in heart stents, appropriate use criteria for imaging in nonvalvular heart disease are released, ACOG updates guidance on hypertension in pregnancy, and more losartan lots are recalled.
This week in Cardiocast, the Hospital Readmissions Reduction Program may be doing more harm than good, ticagrelor holds no edge over aspirin in CABG patients, weight-loss apps lack evidence, and the Surgeon General sends out an alarm.
This week, the barbershop may become a key battleground in the fight against hypertension, the American Diabetes Association upgrades newer antihyperglycemics, refreshed appropriate use criteria for peripheral artery disease are released, and body mass index as a measure of cardiometabolic risk gets a boost.
This week, the American Heart Association says that statins’ benefits far outweigh the risks, a smartphone app is nearly as good as an ECG at diagnosing STEMI, stroke thrombolysis appears safe in patients prone to GI bleeding, and a new strategy for pausing DOAC therapy works in A-fib patients.
This week, apixaban edges out other DOACs for octogenarians, methotrexate fails to cut cardiovascular events in a large trial,
withdrawing heart failure medications after recovery leads to relapse,
and showing patients their own atherosclerosis may reduce their cardiovascular event risk.
From AHA 2018, an analysis gives clue to how empagliflozin cuts cardiovascular risk, and study findings challenge cholesterol guidelines for patients with type 1 diabetes. Also, we take a closer look at how smoke-free policies affect blood pressure, and how magazine-ranked "Best Hospitals" actually perform.